Xtl Biopharmaceuticals (XTLB) Non Operating Income (2009 - 2024)
Xtl Biopharmaceuticals (XTLB) posted Non Operating Income of $427000.0 for Q4 2024, up 102.37% sequentially from $211000.0 in Q3 2024, and up 608.33% YoY from $60282.4 in Q1 2024.
Xtl Biopharmaceuticals (XTLB) Non Operating Income (2009 - 2024) Analysis & Trends
Xtl Biopharmaceuticals has reported Non Operating Income for 16 years, with the latest figure at $427000.0 in Q4 2024.
- Quarterly Non Operating Income rose 608.33% year-over-year to $427000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $1.0 million (up 199.8% YoY) and the FY2025 annual result came in at $929000.0, down 8.47% from the prior year.
- Non Operating Income advanced to $427000.0 in Q4 2024 per XTLB's latest filing, from $211000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $2.4 million in Q4 2021 and troughed at -$888000.0 in Q2 2020.
- A 5-year average of -$50450.0 and a median of -$142500.0 in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income sank 188.48% in 2023, then surged 608.33% in 2024.
- Over 5 years, Non Operating Income stood at -$819000.0 in 2020, then jumped by 390.72% to $2.4 million in 2021, then slumped by 121.97% to -$523000.0 in 2022, then jumped by 83.94% to -$84000.0 in 2023, then soared by 608.33% to $427000.0 in 2024.
- According to Business Quant data, Non Operating Income over the past three periods registered $427000.0, $211000.0, and -$283000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Xtl Biopharmaceuticals | 2.64 Bn | 2.64 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 427,000.00 |
| Sep 30, 2024 | 211,000.00 |
| Jun 30, 2024 | -283,000.00 |
| Mar 31, 2024 | 660,000.00 |
| Dec 31, 2023 | -84,000.00 |
| Sep 30, 2023 | -64,000.00 |
| Jun 30, 2023 | -201,000.00 |
| Mar 31, 2023 | -668,000.00 |
| Dec 31, 2022 | -523,000.00 |
| Sep 30, 2022 | -617,000.00 |
| Jun 30, 2022 | -83,000.00 |
| Mar 31, 2022 | 755,000.00 |
| Dec 31, 2021 | 2.38 Mn |
| Sep 30, 2021 | -585,000.00 |
| Jun 30, 2021 | -847,000.00 |
| Mar 31, 2021 | 518,000.00 |
| Dec 31, 2020 | -819,000.00 |
| Sep 30, 2020 | -729,000.00 |
| Jun 30, 2020 | -888,000.00 |
| Mar 31, 2020 | 430,000.00 |